A Normal Breather
As the market pushed sharply higher following its early-October low (10% or so in the S&P 500, 12%-plus in the Nasdaq), rising seven out of eight weeks, the worries of the world (trade wars, slowing economic growth, even impeachment) were slowly As...
Read More
This portfolio stock shares are down 7% as investors worry about a potential pharmaceutical competitor.
Read More
Our Emerging Markets Timer as found support in recent weeks, but that hasn’t been enough to produce a new buy signal.
Read More
Not a lot has changed since last week’s issue—overall, the cannabis sector remains in a correction—but there are a few stocks worthy of an update.
Read More
Short-term, the market remains under pressure, buffeted by the selling of investors scared by the prospects of an extended tariff war, but long-term, the trend remains up, so we still see the current weakness as a normal correction.
Read More
December: Time for a Portfolio Shake-Up
Here we are in December, an interesting time in the stock market, as excessive price movements culminate, often reversing course in January. On the bullish side, you may have owned stocks that rose an abnormal amount, all year We...
Read More
The Smart Money is Moving In
It’s common knowledge among experienced investors that the price of a company’s stock, at any one time, is imperfectly related to the company’s actual value.
Other factors that affect the price include estimates of the company’s future revenues, earnings profit...
Read More
This retail stock reported fiscal 2020 third quarter results (January year end).
Read More
Mostly Sunny, Chance of Passing Showers
Seven weeks ago, the market was getting hit and growth stocks were looking awful. We were definitely cautious, but on this page we also wrote the following:
“We don’t want to sound too negative. It’s still a bull market, we...
Read More
Market: Great. Growth Stocks: Just OK
Ever since the indexes turned on a dime at the beginning of this year, we’ve been leaning bullish on the general market, and in recent months, even as things have chopped around and there’s been an avalanche of we’ve...
Read More
Yesterday, the House Judiciary Committee approved the Marijuana Opportunity Reinvestment and Expungement Act (MORE Act), which has Democratic Presidential candidate and former prosecutor Kamala Harris as one of its sponsors.
Read More
Short-term, the market remains under pressure, buffeted by the selling of investors scared by the prospects of an extended tariff war, but long-term, the trend remains up, so we still see the current weakness as a normal correction.
Read More
A leading provider of financial advice joins the Special Situation Stock Portfolio as a Strong Buy.
Read More
Our Emerging Markets Timer as found support in recent weeks, but that hasn’t been enough to produce a new buy signal.
Read More
I’m making four changes to the portfolio today.
Read More
Everybody knows Alphabet, or Google. But sometimes GOOGL stock gets surprisingly undervalued. When it happens, you need to pounce.
Read More
Short-term, the market remains under pressure, buffeted by the selling of investors scared by the prospects of an extended tariff war, but long-term, the trend remains up, so we still see the current weakness as a normal correction.
Read More
I’ve made my contempt for the media rather clear in my weekly commentaries at Cabot Undervalued Stocks Advisor, and in my frequent radio appearances.
Read More
With stocks at fresh highs, is a stock market top imminent? Here are five ways to know if the bull market is starting to die of old age.
Read More
Three portfolio stocks report third-quarter results.
Read More
